Anke Huckriede

5.5k citations
119 papers · 4.3k · h-index 38

Impact in

Papers in

  • Epidemiology 67
    • Influenza Virus Research Studies 54
    • Respiratory viral infections research 21
  • Immunology 49
    • Immunotherapy and Immune Responses 26
    • Immune Response and Inflammation 24
    • Immune Cell Function and Interaction 13
Co-authors
Jan Wilschut (40 shared papers)Laura Bungener (18 shared papers)Wouter L.J. Hinrichs (31 shared papers)Henderik W. Frijlink (29 shared papers)Toos Daemen (13 shared papers)Wouter ter Veer (12 shared papers)Felix Geeraedts (6 shared papers)Etienne Agsteribbe (7 shared papers)
Journals
Vaccine (20 papers)Frontiers in Immunology (8 papers)PLoS ONE (5 papers)Journal of Controlled Release (5 papers)European Journal of Pharmaceutics and Biopharmaceutics (4 papers)
Partner nations
NetherlandsUnited StatesGermany

In The Last Decade

Anke Huckriede

117 papers receiving 4.2k citations

Peers

Anke Huckriede
Comparison fields: 5 of 110
  • Pharmaceutical Science 642
  • Immunology 1.6k
  • Epidemiology 1.6k
  • Infectious Diseases 794
  • Microbiology 152
Replace Germain J. P. Fernando with:
Germain J. P. Fernando Australia
Richard T. Kenney United States
Helmut Hahn Germany
Giampietro Corradin Switzerland
Herman F. Staats United States
Sylvie Bertholet United States
Mark A. Tomai United States
Bram Slütter Netherlands
Yoshikazu Yuki Japan
Ali Khamesipour Iran
Anke Huckriede relative to Germain J. P. Fernando Australia Germain J. P. Fernando's profile →
Citations per field
00.5×1.5×2×2.4×
Germain J. P. Fernando · 1×
Citations per year

Countries citing papers authored by Anke Huckriede

Since Specialization
Citations

This map shows the geographic impact of Anke Huckriede's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anke Huckriede with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anke Huckriede more than expected).

Fields of papers citing papers by Anke Huckriede

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anke Huckriede. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anke Huckriede. The network helps show where Anke Huckriede may publish in the future.

Co-authors

The 25 scholars most cited alongside Anke Huckriede, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Anke Huckriede Line = papers co-authored together Anke Huckriede links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 119 papers — load more, or switch the sort, to bring in the rest.

#Work
1
N-Trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: Biological properties and immunogenicity in a mouse model
Vaccine ·Maryam Amidi, Stefan Romeijn, J. Coos Verhoef, Hans E. Junginger, Laura Bungener, Anke Huckriede, Daan J.A. Crommelin, Wim Jiskoot
2006220
2
The virosome concept for influenza vaccines
Vaccine ·Anke Huckriede, Laura Bungener, Toon Stegmann, Toos Daemen, (unknown), A.M. Palache, Jan Wilschut
2005205
3
Superior Immunogenicity of Inactivated Whole Virus H5N1 Influenza Vaccine is Primarily Controlled by Toll-like Receptor Signalling
PLoS Pathogens ·Felix Geeraedts, Nadège Goutagny, Veit Hornung, Martina Severa, Aalzen de Haan, Judith G. Pool, Jan Wilschut, Katherine A. Fitzgerald, Anke Huckriede
2008193
4
Development of Stable Influenza Vaccine Powder Formulations: Challenges and Possibilities
Pharmaceutical Research ·J-P. Amorij, Anke Huckriede, J. Wilschut, Henderik W. Frijlink, Wouter L.J. Hinrichs
2008161
5
Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection
Vaccine ·Laura Bungener, Felix Geeraedts, Wouter ter Veer, (unknown), Jan Wilschut, Anke Huckriede
2008136
6
Microneedle arrays for the transcutaneous immunization of diphtheria and influenza in BALB/c mice
Journal of Controlled Release ·Zhi Ding, F.J. Verbaan, Maytal Bivas‐Benita, Laura Bungener, Anke Huckriede, Dirk‐Jan van den Berg, Gideon Kersten, Joke A. Bouwstra
2009131
7
Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice
Vaccine ·J-P. Amorij, Vinay Saluja, Arjen H. Petersen, Wouter L.J. Hinrichs, Anke Huckriede, Henderik W. Frijlink
2007125
8
GLA-SE, a Synthetic Toll-like Receptor 4 Agonist, Enhances T-Cell Responses to Influenza Vaccine in Older Adults
The Journal of Infectious Diseases ·Hayedeh Behzad, Anke Huckriede, Laura Haynes, Beth Gentleman, Krysta M. Coyle, Jan Wilschut, Tobias R. Kollmann, Steven G. Reed, Janet E. McElhaney
2011112
9
Needle-free influenza vaccination
The Lancet Infectious Diseases ·Jean‐Pierre Amorij, Wouter L.J. Hinrichs, Henderik W. Frijlink, Jan Wilschut, Anke Huckriede
2010100
10
Safety and tolerability evaluation of the use of Montanide ISA™51 as vaccine adjuvant: A systematic review
Human Vaccines & Immunotherapeutics ·Eva van Doorn, Heng Liu, Anke Huckriede, Eelko Hak
2015100
11
Rational design of an influenza subunit vaccine powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying
Vaccine ·J-P. Amorij, J. Meulenaar, Wouter L.J. Hinrichs, Thomas Stegmann, Anke Huckriede, Frans Coenen, Henderik W. Frijlink
200794
12
Virosomes for antigen and DNA delivery
Advanced Drug Delivery Reviews ·Toos Daemen, A DEMARE, Laura Bungener, (unknown), Anke Huckriede, J. Wilschut
200493
13
Towards tailored vaccine delivery: Needs, challenges and perspectives
Journal of Controlled Release ·Jean‐Pierre Amorij, Gideon Kersten, Vinay Saluja, Wouter F. Tonnis, Wouter L.J. Hinrichs, Bram Slütter, Suzanne M. Bal, Joke A. Bouwstra, Anke Huckriede, Wim Jiskoot
201288
14
Generation of heat shock protein-based vaccines by intracellular loading of gp96 with antigenic peptides
Immunology Letters ·Astrid P. Heikema, Etienne Agsteribbe, Jan Wilschut, Anke Huckriede
199778
15
Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity
Vaccine ·Laura Bungener, Anke Huckriede, Arjan de Mare, Jacqueline de Vries‐Idema, Jan Wilschut, Toos Daemen
200478
16
A Fatal, Systemic Mitochondrial Disease with Decreased Mitochondrial Enzyme Activities, Abnormal Ultrastructure of the Mitochondria and Deficiency of Heat Shock Protein 60
Biochemical and Biophysical Research Communications ·Etienne Agsteribbe, Anke Huckriede, Marten Veenhuis, M.H.J. Ruiters, Klary E. Niezen‐Koning, Ola H. Skjeldal, Kari Skullerud, Radhey S. Gupta, Richard L. Hallberg, O.P. Vandiggelen, H.R. Scholte
199376
17
Whole inactivated virus influenza vaccine is superior to subunit vaccine in inducing immune responses and secretion of proinflammatory cytokines by DCs
Influenza and Other Respiratory Viruses ·Felix Geeraedts, Laura Bungener, Judith G. Pool, Wouter ter Veer, Jan Wilschut, Anke Huckriede
200875
18
Development of a dried influenza whole inactivated virus vaccine for pulmonary immunization
Vaccine ·Sandrine Audouy, Gieta van der Schaaf, Wouter L.J. Hinrichs, Henderik W. Frijlink, Jan Wilschut, Anke Huckriede
201173
19
Induction of Heterosubtypic Cross-Protection against Influenza by a Whole Inactivated Virus Vaccine: The Role of Viral Membrane Fusion Activity
PLoS ONE ·Natalija Budimir, Anke Huckriede, Tjarko Meijerhof, Louis Boon, Emma Gostick, David A. Price, Jan Wilschut, Aalzen de Haan
201273
20
Induction of cytotoxic T lymphocyte activity by fusion-active peptide-containing virosomes
Vaccine ·A. Arkema, Anke Huckriede, Pieter Schoen, Jan Wilschut, Toos Daemen
200069

About Anke Huckriede

Anke Huckriede is a scholar working on Epidemiology, Immunology, Molecular Biology, Infectious Diseases and Pulmonary and Respiratory Medicine, having authored 119 papers that have together received 4.3k indexed citations. Recurring topics across this work include Influenza Virus Research Studies (54 papers), Immunotherapy and Immune Responses (26 papers), Immune Response and Inflammation (24 papers), Respiratory viral infections research (21 papers), Immune Cell Function and Interaction (13 papers), Inhalation and Respiratory Drug Delivery (11 papers), Viral gastroenteritis research and epidemiology (8 papers) and Monoclonal and Polyclonal Antibodies Research (8 papers). The work is most often cited by research in Pharmaceutical Science (642 citations), Immunology (1.6k citations), Epidemiology (1.6k citations), Infectious Diseases (794 citations) and Microbiology (152 citations). Anke Huckriede has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include Jan Wilschut, Laura Bungener, Wouter L.J. Hinrichs, Henderik W. Frijlink, Toos Daemen, Wouter ter Veer, Felix Geeraedts, Etienne Agsteribbe, Aalzen de Haan and Jacqueline de Vries‐Idema. Their work appears in journals such as Vaccine, Frontiers in Immunology, PLoS ONE, Journal of Controlled Release and European Journal of Pharmaceutics and Biopharmaceutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Germain J. P. FernandoBreakdown of academic impact, for papers by Richard T. KenneyBreakdown of academic impact, for papers by Helmut HahnBreakdown of academic impact, for papers by Giampietro CorradinBreakdown of academic impact, for papers by Herman F. StaatsBreakdown of academic impact, for papers by Sylvie BertholetBreakdown of academic impact, for papers by Mark A. TomaiBreakdown of academic impact, for papers by Bram SlütterBreakdown of academic impact, for papers by Yoshikazu YukiBreakdown of academic impact, for papers by Ali Khamesipour